Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin)	MSD	Ongoing	(Sitagliptin / Metformin)	3	MK0431-170	King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa)
A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study]	Roche	Ongoing	trastuzumab	3	MO28048	King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh)
A Phase III Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy	MSD	Ongoing	SITAGLIPTIN/ METFORMIN XR	3	MK0431A XR-289	King Khalid University Hospital (Riyadh)
A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control	MSD	Ongoing	Sitagliptin	3	MK0431-083	King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Hospital NG (Al Ahsa), Al-Noor Specialist Hospital (Makkah)
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)	AstraZeneca	Ongoing	Ticagrelor	3b	D513BC00001	King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad University Hospital (Al-Khobar), Saud Al-Babtain Cardiac Center (Dammam)
"An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction"	Roche	Ongoing	Trastuzumab SC	3b	ML28851	King Khalid University Hospital (Riyadh), International Medical Center (Jeddah)
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'	AstraZeneca	Ongoing	Budesonide / Formoterol / Budesonide / Terbutaline	3	D589SC00003	Armed Forces Hospital (Dhahran), King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah)
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4	Novartis	Ongoing	Everolimus/ Afinitor	3	CRAD001T2302	King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy	Novartis	Completed	Everolimus	3	CRAD001N2301	King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma (EVERMORE).	Novartis	Ongoing	Everolimus	2	CRAD001LIC01	King Faisal Specialist Hospital and Research Center (Riyadh)